{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:19:05Z","timestamp":1771017545333,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.4065\/81.12.1579","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"1579-1588","source":"Crossref","is-referenced-by-count":93,"title":["Ezetimibe\/Simvastatin vs Atorvastatin in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia: The VYTAL Study"],"prefix":"10.4065","volume":"81","author":[{"given":"Ronald B.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Mazzone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth S.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Polis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.12.1579_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/diacare.21.1.69","article-title":"Impact of diabetes on mortality after the first myocardial infarction","volume":"21","author":"Miettinen","year":"1998","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.4065\/81.12.1579_bib2","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/diacare.29.s1.06.s4","article-title":"Standards of medical care in diabetes\u20142006","volume":"29","author":"American Diabetes Association","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4065\/81.12.1579_bib3","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.crd.0000188034.76283.5e","article-title":"Management of dyslipidemia in diabetes","volume":"14","author":"Solano","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.4065\/81.12.1579_bib4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes"},{"key":"10.4065\/81.12.1579_bib5","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1136\/bmj.38793.468449.AE","article-title":"Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials","volume":"332","author":"Costa","year":"2006","journal-title":"BMJ"},{"key":"10.4065\/81.12.1579_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines [published correction appears in Circulation. 2004;110:763","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.4065\/81.12.1579_bib7","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.4065\/81.12.1579_bib8","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.4065\/81.12.1579_bib9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366:1358]","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/81.12.1579_bib10","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2337\/diacare.28.5.1029","article-title":"The challenge of achieving national cholesterol goals in patients with diabetes","volume":"28","author":"Kennedy","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4065\/81.12.1579_bib11","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4065\/80.5.587","article-title":"A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) trial","volume":"80","author":"Pearson","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.12.1579_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ahj.2004.11.023","article-title":"Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study [published correction appears in Am Heart J. 2005;149:882]","volume":"149","author":"Ballantyne","year":"2005","journal-title":"Am Heart J"},{"key":"10.4065\/81.12.1579_bib13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.amjcard.2004.02.060","article-title":"Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia","volume":"93","author":"Ballantyne","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.12.1579_bib14","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1185\/030079905X50642","article-title":"Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials","volume":"21","author":"Catapano","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"10.4065\/81.12.1579_bib15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1368-5031.2004.00289.x","article-title":"Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia","volume":"58","author":"Davidson","year":"2004","journal-title":"Int J Clin Pract"},{"key":"10.4065\/81.12.1579_bib16","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1185\/030079906X132721","article-title":"Lipid-altering efficacy of the ezetimibe\/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients","volume":"22","author":"Catapano","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.4065\/81.12.1579_bib17","author":"International Diabetes Federation"},{"key":"10.4065\/81.12.1579_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.hco.0000200416.65370.a0","article-title":"Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute scientific statement","volume":"21","author":"Grundy","year":"2006","journal-title":"Curr Opin Cardiol"},{"key":"10.4065\/81.12.1579_bib19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.4065\/81.12.1579_bib20","first-page":"3","article-title":"LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD","volume":"7","author":"McKenney","year":"2005","journal-title":"MedGenMed"},{"key":"10.4065\/81.12.1579_bib21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1111\/j.1368-5031.2005.00714.x","article-title":"Lipid-altering efficacy of switching from atorvastatin 10 mg\/day to ezetimibe\/simvastatin 10\/20 mg\/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease","volume":"59","author":"Barrios","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.4065\/81.12.1579_bib22","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4065\/81.12.1579_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.4065\/81.12.1579_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.diabres.2005.03.032","article-title":"Prevalence and control of dyslipidemia among persons with diabetes in the United States","volume":"70","author":"Jacobs","year":"2005","journal-title":"Diabetes Res Clin Pract"},{"issue":"suppl 12A","key":"10.4065\/81.12.1579_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.amjmed.2005.09.003","article-title":"Statin use in a \u201creal-world\u201d clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial","volume":"118","author":"Koren","year":"2005","journal-title":"Am J Med"},{"issue":"1, suppl","key":"10.4065\/81.12.1579_bib26","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ahj.2004.04.027","article-title":"Focus on high-density lipoproteins in reducing cardiovascular risk","volume":"148","author":"Brewer","year":"2004","journal-title":"Am Heart J"},{"key":"10.4065\/81.12.1579_bib27","doi-asserted-by":"crossref","first-page":"755.e1","DOI":"10.1016\/j.ahj.2005.12.007","article-title":"The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events","volume":"151","author":"Koro","year":"2006","journal-title":"Am Heart J [serial online]"},{"key":"10.4065\/81.12.1579_bib28","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/81.12.1579_bib29","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2337\/diacare.28.3.690","article-title":"Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein","volume":"28","author":"Malik","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4065\/81.12.1579_bib30","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.2337\/diacare.27.12.2960","article-title":"Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey","volume":"27","author":"Chen","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4065\/81.12.1579_bib31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.104.489260","article-title":"C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study","volume":"112","author":"Best","year":"2005","journal-title":"Circulation"},{"issue":"suppl A","key":"10.4065\/81.12.1579_bib32","first-page":"335A","article-title":"Ezetimibe\/simvastatin versus atorvastatin for attainment of apolipoprotein B and C-reactive protein goals: a VYVA substudy [abstract]","volume":"47","author":"Ballantyne","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/81.12.1579_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1475-2840-4-7","article-title":"Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study","volume":"4","author":"Berne","year":"2005","journal-title":"Cardiovasc Diabetol [serial online]"},{"issue":"8A","key":"10.4065\/81.12.1579_bib34","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"issue":"8A","key":"10.4065\/81.12.1579_bib35","doi-asserted-by":"crossref","first-page":"32C","DOI":"10.1016\/j.amjcard.2005.12.008","article-title":"Statin safety: an appraisal from the adverse event reporting system","volume":"97","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611609440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611609440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T12:25:24Z","timestamp":1709987124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611609440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["S0025619611609440"],"URL":"https:\/\/doi.org\/10.4065\/81.12.1579","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}